{"id":45195,"date":"2025-10-29T17:40:57","date_gmt":"2025-10-29T09:40:57","guid":{"rendered":"https:\/\/flcube.com\/?p=45195"},"modified":"2025-10-29T17:40:58","modified_gmt":"2025-10-29T09:40:58","slug":"yzy-biopharma-y225-patent-secures-hemlibra-biosimilar-pathway-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45195","title":{"rendered":"YZY Biopharma Y225 Patent Secures Hemlibra Biosimilar Pathway in China"},"content":{"rendered":"\n<p><strong>Wuhan YZY Biopharma Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2496:HKG\">HKG: 2496<\/a>) announced today that its high\u2011concentration antibody formulation for the biosimilar <strong>Y225<\/strong>\u2014a therapeutic equivalent to Roche\u2019s Hemlibra (emicizumab)\u2014has been granted an invention patent in China. The patent (No.\u202fZL\u202f202510126091.1) was approved by the National Intellectual Property Administration (CNIPA) under a prioritized examination, with the authorization publication (CN\u202f119950703B) issued on 28\u202fOct\u202f2025.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-patent-highlights\"><strong>Patent Highlights<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Scope<\/strong> \u2013 Covers the antibody formulation technology that enables a high\u2011concentration, subcutaneous dosing regimen identical to Hemlibra.<\/li>\n\n\n\n<li><strong>Strategic Value<\/strong> \u2013 Breaks through the existing formulation patent held by Roche (expiring 2037) and allows Y225 to enter the Chinese market up to six years before the originator\u2019s patent expiry.<\/li>\n\n\n\n<li><strong>Application<\/strong> \u2013 Filed on 27\u202fJan\u202f2025; granted after expedited review, underscoring the urgency of addressing unmet needs in hemophilia care.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-y225-a-game-changing-hemophilia-a-therapy\"><strong>Y225 \u2013 A Game\u2011Changing Hemophilia A Therapy<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong> \u2013 A bispecific antibody that mimics coagulation Factor\u202fVIII, restoring clotting ability in patients with or without Factor\u202fVIII inhibitors.<\/li>\n\n\n\n<li><strong>Clinical Advantage<\/strong> \u2013 Once\u2011every\u2011four\u2011week dosing with subcutaneous injection mirrors Hemlibra\u2019s convenience, yet the new formulation removes the high\u2011concentration barrier that has limited biosimilar development.<\/li>\n\n\n\n<li><strong>Regulatory Status<\/strong> \u2013 Y225\u2019s Investigational New Drug (IND) application has been accepted by the National Medical Products Administration (NMPA) (Acceptance Nos.:\u202fCXSL2500899,\u202fCXSL2500897).<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact\"><strong>Market Impact<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Early Access<\/strong> \u2013 The patent breakthrough positions Y225 to launch in China as early as 2029, potentially delivering a cost\u2011effective alternative to the >\u202fUSD\u202f5\u202fbillion global Hemlibra sales in 2024.<\/li>\n\n\n\n<li><strong>Patient Reach<\/strong> \u2013 By overcoming formulation restrictions, Y225 could dramatically expand treatment options for hemophilia A patients across China, where the prevalence of the disease and the need for affordable therapies remain high.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) announced today that its high\u2011concentration antibody formulation for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45196,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,61],"tags":[928,73,24,163,137],"class_list":["post-45195","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-legal-ip","tag-hkg-2496","tag-patents","tag-rare-orphan-disease-drugs","tag-roche","tag-yzy-biopharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>YZY Biopharma Y225 Patent Secures Hemlibra Biosimilar Pathway in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) announced today that its high\u2011concentration antibody formulation for the biosimilar Y225\u2014a therapeutic equivalent to Roche\u2019s Hemlibra (emicizumab)\u2014has been granted an invention patent in China. The patent (No.\u202fZL\u202f202510126091.1) was approved by the National Intellectual Property Administration (CNIPA) under a prioritized examination, with the authorization publication (CN\u202f119950703B) issued on 28\u202fOct\u202f2025.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45195\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"YZY Biopharma Y225 Patent Secures Hemlibra Biosimilar Pathway in China\" \/>\n<meta property=\"og:description\" content=\"Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) announced today that its high\u2011concentration antibody formulation for the biosimilar Y225\u2014a therapeutic equivalent to Roche\u2019s Hemlibra (emicizumab)\u2014has been granted an invention patent in China. The patent (No.\u202fZL\u202f202510126091.1) was approved by the National Intellectual Property Administration (CNIPA) under a prioritized examination, with the authorization publication (CN\u202f119950703B) issued on 28\u202fOct\u202f2025.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45195\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-29T09:40:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-29T09:40:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2911.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45195#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45195\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"YZY Biopharma Y225 Patent Secures Hemlibra Biosimilar Pathway in China\",\"datePublished\":\"2025-10-29T09:40:57+00:00\",\"dateModified\":\"2025-10-29T09:40:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45195\"},\"wordCount\":300,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45195#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2911.webp\",\"keywords\":[\"HKG: 2496\",\"Patents\",\"Rare \\\/ orphan disease drugs\",\"Roche\",\"YZY Biopharma\"],\"articleSection\":[\"Company\",\"Legal \\\/ IP\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45195#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45195\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45195\",\"name\":\"YZY Biopharma Y225 Patent Secures Hemlibra Biosimilar Pathway in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45195#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45195#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2911.webp\",\"datePublished\":\"2025-10-29T09:40:57+00:00\",\"dateModified\":\"2025-10-29T09:40:58+00:00\",\"description\":\"Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) announced today that its high\u2011concentration antibody formulation for the biosimilar Y225\u2014a therapeutic equivalent to Roche\u2019s Hemlibra (emicizumab)\u2014has been granted an invention patent in China. The patent (No.\u202fZL\u202f202510126091.1) was approved by the National Intellectual Property Administration (CNIPA) under a prioritized examination, with the authorization publication (CN\u202f119950703B) issued on 28\u202fOct\u202f2025.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45195#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45195\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45195#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2911.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2911.webp\",\"width\":1080,\"height\":608,\"caption\":\"YZY Biopharma Y225 Patent Secures Hemlibra Biosimilar Pathway in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45195#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"YZY Biopharma Y225 Patent Secures Hemlibra Biosimilar Pathway in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"YZY Biopharma Y225 Patent Secures Hemlibra Biosimilar Pathway in China - Insight, China&#039;s Pharmaceutical Industry","description":"Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) announced today that its high\u2011concentration antibody formulation for the biosimilar Y225\u2014a therapeutic equivalent to Roche\u2019s Hemlibra (emicizumab)\u2014has been granted an invention patent in China. The patent (No.\u202fZL\u202f202510126091.1) was approved by the National Intellectual Property Administration (CNIPA) under a prioritized examination, with the authorization publication (CN\u202f119950703B) issued on 28\u202fOct\u202f2025.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45195","og_locale":"en_US","og_type":"article","og_title":"YZY Biopharma Y225 Patent Secures Hemlibra Biosimilar Pathway in China","og_description":"Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) announced today that its high\u2011concentration antibody formulation for the biosimilar Y225\u2014a therapeutic equivalent to Roche\u2019s Hemlibra (emicizumab)\u2014has been granted an invention patent in China. The patent (No.\u202fZL\u202f202510126091.1) was approved by the National Intellectual Property Administration (CNIPA) under a prioritized examination, with the authorization publication (CN\u202f119950703B) issued on 28\u202fOct\u202f2025.","og_url":"https:\/\/flcube.com\/?p=45195","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-29T09:40:57+00:00","article_modified_time":"2025-10-29T09:40:58+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2911.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45195#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45195"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"YZY Biopharma Y225 Patent Secures Hemlibra Biosimilar Pathway in China","datePublished":"2025-10-29T09:40:57+00:00","dateModified":"2025-10-29T09:40:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45195"},"wordCount":300,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45195#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2911.webp","keywords":["HKG: 2496","Patents","Rare \/ orphan disease drugs","Roche","YZY Biopharma"],"articleSection":["Company","Legal \/ IP"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45195#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45195","url":"https:\/\/flcube.com\/?p=45195","name":"YZY Biopharma Y225 Patent Secures Hemlibra Biosimilar Pathway in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45195#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45195#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2911.webp","datePublished":"2025-10-29T09:40:57+00:00","dateModified":"2025-10-29T09:40:58+00:00","description":"Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) announced today that its high\u2011concentration antibody formulation for the biosimilar Y225\u2014a therapeutic equivalent to Roche\u2019s Hemlibra (emicizumab)\u2014has been granted an invention patent in China. The patent (No.\u202fZL\u202f202510126091.1) was approved by the National Intellectual Property Administration (CNIPA) under a prioritized examination, with the authorization publication (CN\u202f119950703B) issued on 28\u202fOct\u202f2025.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45195#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45195"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45195#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2911.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2911.webp","width":1080,"height":608,"caption":"YZY Biopharma Y225 Patent Secures Hemlibra Biosimilar Pathway in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45195#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"YZY Biopharma Y225 Patent Secures Hemlibra Biosimilar Pathway in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2911.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45195"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45195\/revisions"}],"predecessor-version":[{"id":45197,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45195\/revisions\/45197"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45196"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45195"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45195"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}